Sermorelin acetate is a synthetic peptide often used in research settings to study growth hormone (GH) regulation. It is an analog of growth hormone–releasing hormone (GHRH), specifically corresponding to the first 29 amino acids of the natural GHRH molecule—the portion responsible for biological activity.

Mechanism of action (research context):
Sermorelin binds to GHRH receptors in the anterior pituitary gland, stimulating the release of endogenous growth hormone. This, in turn, can increase circulating levels of insulin-like growth factor 1 (IGF-1), which mediates many downstream physiological effects associated with growth hormone signaling.

Key properties:

• Structure: Peptide (29 amino acids; often called GRF 1-29)
• Form: Typically studied as the acetate salt for stability
• Half-life: Short (minutes), due to rapid enzymatic degradation
• Administration in studies: Commonly via subcutaneous or intravenous routes in experimental models

Research applications:

• Investigating hypothalamic–pituitary axis function
• Studying pulsatile vs. continuous GH secretion patterns
• Evaluating age-related changes in GH production
• Exploring metabolic, anabolic, and endocrine signaling pathways
• Comparing GHRH analogs with other GH secretagogues (e.g., ghrelin mimetics)

Distinguishing features vs. exogenous GH:

• Stimulates natural GH release rather than supplying GH directly
• Preserves physiological feedback loops (e.g., somatostatin regulation)
• Produces more pulsatile GH secretion in experimental models

Limitations in research:

• Short duration of action requires repeated dosing or infusion protocols
• Effects depend on intact pituitary function
• Variable response across subjects due to age, baseline GH levels, or endocrine status

Because of its role as a GHRH analog, sermorelin is primarily used as a tool to probe endocrine function rather than as a direct replacement for growth hormone in experimental designs.